文献速递角膜与眼表疾病

UC-MSC治疗BAC诱导干眼模型的机制:TSG-6依赖抑制Th17/CCL20-CCR6趋化轴

Mechanistic Insights Into UC-MSC Therapy in a BAC-Induced Dry Eye Model: TSG-6-Dependent Inhibition of the Th17/CCL20-CCR6 Chemotactic Axis.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

该研究利用高渗应激的角膜上皮细胞和苯扎氯铵诱导的小鼠干眼模型,通过滴眼液体内给药和Transwell共培养体外给药,探究人脐带间充质干细胞(UCMSCs)的治疗潜力及TSG-6的作用。结果显示UCMSCs改善泪液分泌、减少角膜损伤、增加杯状细胞密度、抑制促炎因子和Th17细胞,且这些益处依赖TSG-6;TSG-6通过抑制NF-κB(而非MAPK)减少上皮CCL20产生,并抑制树突状细胞成熟和抗原提呈,从而减少Th17迁移和分化。干眼患者泪液中CCL20、IL-17A和IL-6升高且与严重程度相关。

要点

  • UCMSCs滴眼改善BAC诱导小鼠干眼的泪液分泌、角膜损伤和杯状细胞密度,并抑制TNF-α、IL-1β、IL-6和Th17细胞。
  • UCMSCs的上述治疗效应依赖TSG-6:敲低TSG-6的UCMSCs失去保护作用。
  • TSG-6通过抑制NF-κB(非MAPK)减少高渗诱导的上皮CCL20,并抑制DC成熟和抗原提呈以减少Th17分化。

核心结论

  • UCMSCs主要通过分泌TSG-6缓解干眼,TSG-6双靶向CCL20/CCR6轴抑制上皮NF-κB依赖的CCL20产生并抑制DC成熟和功能,减少Th17迁移和分化。
  • TSG-6/Th17/CCL20-CCR6轴是干眼有前景的治疗靶点。

研究设计与样本

  • 体外使用高渗应激的角膜上皮细胞,体内使用苯扎氯铵诱导的小鼠干眼模型,UCMSCs体内经滴眼液给药、体外经Transwell共培养给药。
  • 使用敲低TSG-6的UCMSCs(shTSG-6)检验TSG-6的作用,并进行功能、组织学和分子分析,包括人泪液样本。

主要发现

  • UCMSCs改善泪液分泌、减少角膜损伤、增加杯状细胞密度,并抑制促炎细胞因子(TNF-α、IL-1β和IL-6)和Th17细胞,这些益处依赖TSG-6。
  • TSG-6通过抑制NF-κB(而非MAPK)抑制高渗诱导的上皮CCL20,破坏Th17募集。
  • TSG-6抑制树突状细胞成熟和抗原提呈,减少Th17分化。
  • 干眼患者泪液中CCL20、IL-17A和IL-6升高,且与疾病严重程度相关。

临床怎么用

  • UCMSCs滴眼可能成为干眼治疗策略,其疗效依赖TSG-6。
  • TSG-6/Th17/CCL20-CCR6轴可作为干眼治疗靶点,泪液CCL20、IL-17A和IL-6或与严重程度相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aims to investigate the therapeutic potential of umbilical cord-derived mesenchymal stem cells (UCMSCs) for dry eye disease (DED) and elucidate the underlying mechanisms, with particular focus on the role of TSG-6 in modulating the pathogenic Th17/CCL20-CCR6 inflammatory axis. METHODS: Using in vitro hyperosmolar-stressed corneal epithelial cells and a benzalkonium chloride-induced murine DED model, UCMSCs were administered via eye drops in vivo and via Transwell co-culture in vitro. The role of the tumor necrosis factor α stimulated gene/protein 6 (TSG-6) was examined using knockdown UCMSCs (shTSG-6). Functional, histological, and molecular analyses were performed, including human tear samples. RESULTS: UCMSCs improved tear secretion, reduced corneal damage, increased goblet cell density, and suppressed pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) and Th17 cells. These benefits were TSG-6-dependent. Mechanistically, TSG-6 inhibited hyperosmolarity-induced CCL20 in the epithelia by suppressing NF-κB (not MAPK), disrupting Th17 recruitment. TSG-6 also suppressed dendritic cell (DC) maturation and antigen presentation, reducing Th17 differentiation. Clinically, the tears of patients with DED showed elevated CCL20, IL-17A, and IL-6, correlating with severity. CONCLUSIONS: This study demonstrates that UCMSCs alleviate DED primarily through the secretion of TSG-6. The TSG-6 mediates the therapeutic effects by dually targeting the CCL20/CCR6 axis, inhibiting NF-κB-dependent CCL20 production in ocular surface epithelia, and suppressing DC maturation and function, leading to reduced Th17 cell migration and differentiation. These findings highlight TSG-6 as a critical mechanistic mediator and suggest the UCMSCs-secreted TSG-6/Th17/CCL20-CCR6 axis as a promising therapeutic target for DED.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Liang Q, Chen Z, Liu Y, et al. Mechanistic Insights Into UC-MSC Therapy in a BAC-Induced Dry Eye Model: TSG-6-Dependent Inhibition of the Th17/CCL20-CCR6 Chemotactic Axis. Invest Ophthalmol Vis Sci. 2026. PMID: 42041174. doi:10.1167/iovs.67.4.61

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。